Liquid Biopsy: a Holy Grail for Cancer Detection.

Biomarkers in MedicineVol. 13, No. 12 CommentaryLiquid biopsy: a holy grail for cancer detectionLynn Sorbara & Sudhir SrivastavaLynn SorbaraDivision of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA & Sudhir Srivastava*Author for correspondence: Tel.: +1 240 276 7040; E-mail Address: Srivasts@mail.nih.govDivision of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USAPublished Online:29 Aug 2019https://doi.org/10.2217/bmm-2019-0201AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: biopsybloodcancer detectioncancer diagnosiscell free DNA (cfDNA)circulating cellsexosomesliquid biopsyplasmaprognosisserumReferences1. National Cancer Institute. Liquid biopsy: using DNA in blood to detect, track, and treat cancer (2017). www.cancer.gov/news-events/cancer-currents-blog/2017/liquid-biopsy-detects-treats-cancer.Google Scholar2. Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6(5), 479–491 (2016).Crossref, Medline, CAS, Google Scholar3. Brock G, Castellanos-Rizaldos E, Hu L, Coticchia C, Skog J. Liquid biopsy for cancer screening, patient stratification and monitoring. Transl. Cancer. Res. 4(3), 280–290 (2015).CAS, Google Scholar4. Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Ann. Oncol. 25(12), 2304–2313 (2014).Crossref, Medline, CAS, Google Scholar5. De Mattos-Arruda L, Mayor R, Ng CK et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat. Commun. 6, 8839 (2015).Crossref, Medline, Google Scholar6. Yanagita M, Redig AJ, Paweletz CP et al. A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR-mutant non-small cell lung cancer patients treated with erlotinib on a Phase II trial. Clin. Cancer Res. 22(24), 6010–6020 (2016).Crossref, Medline, CAS, Google Scholar7. Wang Y, Li L, Douville C et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci. Transl. Med. 10(433), 1–9 (2018).Crossref, Google Scholar8. Yang G, Wan LS. Endometrial biopsy using the Tao brush method. A study of 50 women in a general gynecologic practice. J. Reprod. Med. 45(2), 109–114 (2000).Medline, CAS, Google Scholar9. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. PNAS 105(30), 10513–10518 (2008).Crossref, Medline, CAS, Google Scholar10. Porzycki P, Ciszkowicz E, Semik M, Tyrka M. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool or prostate cancer recognition. Int. Urol. Nephrol. 50(9), 1619–1626 (2018).Crossref, Medline, CAS, Google Scholar11. Su YH, Kim AK, Jain S. Liquid biopsies for hepatocellular carcinoma. J. Lab. Clin. Med. 201, 84–97 (2018).Google Scholar12. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. PNAS 108(23), 9530–9535 (2011).Crossref, Medline, Google Scholar13. Cohen JD, Li L, Wang Y et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359(6378), 926–930 (2018).Crossref, Medline, CAS, Google Scholar14. Vachani A, Whitney DH, Parsons EC et al. Clinical utility of a bronchial genomic classifier in patients with suspected lung cancer. Chest 150(1), 210–218 (2016).Crossref, Medline, Google Scholar15. Ridge JR, Statz S. Exact Sciences' experience with the FDA and CMS parallel review program. Expert Rev. Mol. Diagn. 15(9), 1117–1124 (2015).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByDevelopment and evaluation of safety and effectiveness of novel cancer screening tests for routine clinical use with applications to multicancer detection technologies8 February 2022 | Cancer, Vol. 128, No. S4Emerging Technologies in Markets for the Early Detection of Head and Neck Cancer8 May 2021Strand displacement-triggered G-quadruplex/rolling circle amplification strategy for the ultra-sensitive electrochemical sensing of exosomal microRNAs15 February 2020 | Microchimica Acta, Vol. 187, No. 3 Vol. 13, No. 12 Follow us on social media for the latest updates Metrics Downloaded 153 times History Received 8 May 2019 Accepted 17 May 2019 Published online 29 August 2019 Published in print August 2019 Information© 2019 Future Medicine LtdKeywordsbiopsybloodcancer detectioncancer diagnosiscell free DNA (cfDNA)circulating cellsexosomesliquid biopsyplasmaprognosisserumFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download